Nevertheless, immune resistance induced by higher expressed programmed death ligand‐1 (PD‐L1)after radiotherapy and limited DNA damage due to lung tumor hypoxia still remains one of the main causes of treatment failure after radiotherapy.[4] Thus, effective multi‐functional adjuvants that could enhance radiotherapy‐based lung cancer therapy efficacy are still urgently needed. The gene discussed is CD274; the disease is lung cancer.